Department of Ophthalmology, Asan Medical Center, University of Ulsan, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 138-736, Korea,
Jpn J Ophthalmol. 2014 Mar;58(2):146-54. doi: 10.1007/s10384-014-0305-9. Epub 2014 Jan 31.
To determine the correlation between the duration of macular edema (ME) and visual outcomes among Korean patients with retinal vein occlusion (RVO).
Multicenter, interventional case series. Treatment-naive patients (n = 249) with branch or central RVO (BRVO/CRVO) and ME for <6 months were included. We assessed the correlation between the duration of ME and treatment outcomes including the mean logarithm of the minimum angle of resolution best-corrected visual acuity (logMAR BCVA) improvement, the proportion of patients achieving at least a 3-line gain in BCVA, and the mean reduction in central retinal thickness (CRT) at 6 months.
One hundred and fifty-six patients with BRVO and 93 patients with CRVO were divided into five groups based on the duration of ME (<2, 2-4 weeks, 1-2, 2-3, 3-6 months); the mean baseline BCVA and CRT among the groups did not differ significantly. In BRVO, the mean logarithm of the minimum angle of resolution (logMAR) BCVA improvements in the groups were 0.51, 0.32, 0.17, 0.19, and 0.13, respectively (P = 0.002). The respective percentages of at least 3-line gains were 64, 53, 39, 38, and 21 % (P < 0.001). The BCVA didn't significantly improve in CRVO. The decrease in CRT was not correlated significantly with the duration of ME in either disease.
Treatment of BRVO as early as 2 weeks after onset of ME enhanced the visual outcome; there was no correlation in the patients with CRVO. This finding supports the current trend favoring early treatment to obtain better visual outcomes in patients with BRVO.
确定韩国视网膜静脉阻塞(RVO)患者黄斑水肿(ME)持续时间与视力结果之间的相关性。
多中心、干预性病例系列研究。纳入未经治疗的分支或中央 RVO(BRVO/CRVO)伴 ME 时间<6 个月的患者(n=249)。我们评估了 ME 持续时间与治疗结果之间的相关性,包括平均最小分辨角对数视力(logMAR BCVA)改善、BCVA 至少提高 3 行的患者比例以及中央视网膜厚度(CRT)在 6 个月时的平均降低。
156 例 BRVO 患者和 93 例 CRVO 患者根据 ME 持续时间(<2、2-4 周、1-2、2-3、3-6 个月)分为五组;各组的平均基线 BCVA 和 CRT 无显著差异。在 BRVO 中,各组平均最小分辨角对数视力(logMAR)BCVA 改善分别为 0.51、0.32、0.17、0.19 和 0.13(P=0.002)。至少提高 3 行的比例分别为 64%、53%、39%、38%和 21%(P<0.001)。CRVO 的 BCVA 没有显著改善。在两种疾病中,CRT 的降低与 ME 持续时间均无显著相关性。
BRVO 患者在 ME 发病后 2 周内开始治疗可提高视力结果;CRVO 患者无相关性。这一发现支持了目前的趋势,即在 BRVO 患者中,早期治疗可获得更好的视力结果。